Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescribed drugs’ (INO) inventory in 2025. Inventory forecasts are based mostly on numerous components similar to the corporate’s monetary efficiency, business developments, and general financial situations.
Inovio is a clinical-stage biotechnology firm centered on creating and commercializing DNA-based immunotherapies for infectious ailments and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s at the moment in Section 3 medical trials. Inovio additionally has a pipeline of different DNA-based vaccines in growth for numerous infectious ailments and most cancers indications.
